Anhedonia & Low Libido Post-Antipsychotics: Management Overview

Understanding the Mechanisms

• D2 receptor blockade dampening the mesolimbic reward pathway
• "Neuroleptic-induced deficit syndrome" - emotional blunting from excessive dopamine suppression
• Negative symptoms of the underlying psychotic disorder itself

• Hyperprolactinemia (major contributor - explains ~40% of cases): D2 blockade in the tuberoinfundibular pathway raises prolactin, which suppresses testosterone/estrogen and directly inhibits desire
• Direct dopamine blockade reducing motivation and reward salience
• Sedation and weight gain reducing desire
• Anticholinergic and alpha-1 adrenergic blockade effects
• Maudsley Prescribing Guidelines 15e, pp. 220-224

Step 1 - Antipsychotic Review (Most Impactful)

• Aripiprazole - partial D2 agonist, no prolactin elevation, no sexual adverse effects in monotherapy; can improve sexual function when switched from other antipsychotics or added as adjunct
• Brexpiprazole - similar mechanism (5-HT1A agonist, 5-HT2A antagonist, partial D2 agonist), negligible prolactin increase, no sexual dysfunction in trials
• Cariprazine - same class, not associated with hyperprolactinemia, very low sexual dysfunction rates
• Quetiapine - no prolactin effect; fewer sexual problems
• Lurasidone - does not appear to affect prolactin
• Clozapine - no prolactin effect (though alpha-1 and anticholinergic side effects persist)

• Maudsley Prescribing Guidelines 15e, p. 221

Step 2 - Adjunctive Pharmacology for Anhedonia

Step 3 - Specific Libido Interventions

• Check serum prolactin - if elevated, switching to aripiprazole (or adding it as adjunct) normalizes prolactin rapidly
• Dopamine agonists (cabergoline, bromocriptine) can reduce prolactin but risk worsening psychosis - use cautiously, specialist supervision
• Aripiprazole augmentation to a prolactin-raising antipsychotic (e.g., risperidone + aripiprazole) is a practical approach that preserves antipsychotic efficacy while lowering prolactin

• PDE5 inhibitors (sildenafil, tadalafil) are effective for the erectile component but have no effect on libido or central arousal
• Maudsley 15e explicitly notes these don't address the desire component

• Check testosterone (men) and estrogen/LH/FSH (women) if prolactin is elevated - they may be suppressed secondarily
• Testosterone replacement in hypogonadal men can help libido directly, but requires endocrinology input
• Testosterone patches/gel in women with severe hypogonadism (off-label) has some evidence

Step 4 - Non-pharmacological Options

• rTMS (repetitive transcranial magnetic stimulation) targeting the left DLPFC or reward circuits - growing evidence for both treatment-resistant anhedonia and negative symptoms
• Behavioral activation / structured pleasure scheduling - CBT-based, well-supported
• Aerobic exercise - SMD 0.68 for negative symptoms in the 2026 meta-analysis above; improves dopamine tone and mood

Practical Framework

1. Measure prolactin - if elevated, this is a primary target
2. Review and consider switching antipsychotic to aripiprazole, brexpiprazole, or cariprazine if clinically safe
3. Add bupropion if depression/anhedonia persists and switching isn't feasible - addresses both symptoms
4. Consider vortioxetine or agomelatine specifically for anhedonia with depressive features
5. Add structured exercise as an adjunct (underused but evidence-based)
6. Refer to sexual health clinic if erectile dysfunction or orgasm dysfunction persists after the above

Important: Distinguish whether anhedonia/low libido is drug-induced vs. a primary negative symptom of the psychotic illness - the latter is harder to treat and may reflect inadequate overall symptom control rather than medication side effects specifically.